Table 1.

Baseline characteristics and main outcomes of patients in the study group as a whole (overall) and in patients with undetectable, not available, or detectable anti-PLA2R autoantibodies and according to titer tertile of detectable antibodies considered separately

CharacteristicOverall (N=132)Undetectable (n=20)Not Available (n=31)Detectable (n=81)Lowest Tertile (14–86 RU/ml) (n=27)Middle Tertile (87–204 RU/ml) (n=27)Highest Tertile (>204 RU/ml) (n=27)
Age (y)55.7±15.455.0±17.057.0±18.655.4±13.854.0±11.955.1±15.757.2±14.0
Male sex, n (%)100 (75.8)17 (85.0)21 (67.7)62 (76.5)18 (66.7)24 (88.9)20 (74.1)
Previous duration of proteinuria (mo)25.8 (11.0–70.3)41.0 (10.0–177.1)30.6 (12.0–64.2)25.0 (11.0–64.5)27.2 (10.2–94.4)22.1 (10.9–51.9)21.2 (13.0–50.0)
Previous immunosuppression, n (%)49 (37.1)7 (35.0)9 (29.0)33 (40.7)10(37.0)12(44.4)11(40.7)
B Cell–driven protocol, n (%)102 (77.3)a18 (90.0)13 (42.0)b 71 (87.7)22 (81.5)23 (85.2)26 (96.3)
Clinical parameters
 Body weight (kg)76.3±13.179.5±10.973.8±15.776.3±12.774.6±14.278.5±12.075.8±12.0
 Systolic BP (mmHg)134.3±17.8132.5±15.4130.5±19.2136.0±17.9134.0±15.3136.4±18.6137.9±20.4
 Diastolic BP (mmHg)82.1±10.180.9±9.681.6±13.282.6±9.182.3±9.882.4±9.183.3±8.6
Laboratory parameters
 Serum creatinine (mg/dl)1.21 (1.00–1.73)1.13 (0.94–1.99)1.39 (1.01–1.90)1.21 (1.00–1.71)1.09 (0.97–1.60)1.29 (1.08–1.77)1.26 (0.97–1.87)
 Serum albumin (g/dl)2.21±0.59a 2.69±0.502.28±0.52c 2.08±0.56d2.21±0.612.06±0.511.96±0.57
 Total cholesterol (mg/dl)258 (215–318)230 (184–289)236 (194–318)272 (225–320)c 271 (215–335)281 (239–326)261 (216–319)
 HDL cholesterol (mg/dl)50 (42–63)44 (40–53)51 (45–56)53 (42–66)59 (44–69)53 (45–63)49 (39–69)
 Triglycerides (mg/dl)158 (110–225)160 (131–209)180 (131–230)141 (98–233)127 (88–180)161 (118–265)194 (100–270)
 Proteinuria (g/24h)9.1 (5.8–12.7)6.3 (3.4–12.0)9.2 (6.2–12.0)c 9.8 (5.9–13.4)c 7.4 (4.3–10.5)10.8 (6.7–14.8)c 11.6 (7.6–13.4)
Outcome
 Combined end point84 (63.6)12 (60.0)24 (77.4)48 (59.3)22 (81.5)e 16 (59.3)10 (37.0)b
 Time to combined end point7.1 (3.2–12.2)3.5 (2.4–6.6)8.6 (2.5–15.5)7.4 (3.9–12.2)c 5.4 (4.1–8.8)9.1 (3.5–16.4)11.6 (5.3–24.8)
 Relapse25 (18.9)3 (15.0)8 (25.8)14 (17.3)8 (29.6)4 (14.8)2 (7.4)c
 Time to relapse (mo)37.7 (24.8–49.6)41.8 (15.7–48.1)29.7 (18.8–60.5)41.6 (26.3–50.5)41.6 (30.5–48.4)52.4 (31.4–60.1)30.8 (26.3–35.2)
  • Variables expressed as mean±SD are compared using one-way ANOVA; variables expressed as median and IQR are compared using Kruskal–Wallis test. Categorical variables are expressed in percentage and compared using Pearson chi-squared test or Fisher exact test, as appropriate. The titer range for each tertile is listed in brackets.

  • a P<0.001 among subgroups (undetectable, not available, and detectable or lowest, middle, and highest tertile).

  • b P<0.01 for detectable or not available versus undetectable group and for highest or middle versus lowest tertile.

  • c P<0.05 for detectable or not available versus undetectable group and for highest or middle versus lowest tertile.

  • d P<0.001 for detectable or not available versus undetectable group and for highest or middle versus lowest tertile.

  • e P<0.01 among subgroups (undetectable, not available, and detectable or lowest, middle, and highest tertile).